RALEIGH, NC--(Marketwire - September 01, 2010) -
InoLife Technologies, Inc. (OTCBB:
INOL), a service based healthcare products development, integration and marketing Company, announced today it will provide and market a proprietary metabolizing test to physicians and practitioners to identify how a patient's genetic makeup may affect the body's response to Plavix (colpidogrel). The test will only be made available to physicians.
The Food and Drug Administration recently announced that Plavix must now carry a so-called "black box" warning label after a landmark study revealed that patients who were "non-responders" as a result of a genetic variation were "3.58 times more likely to have a fatal stroke or myocardial infarction."
Plavix, an $8-billion-a-year drug and considered to be the second best selling drug in the world, reduces the risk of heart attack, stroke, and cardiovascular death in patients with cardiovascular disease by making platelets less likely to form blood clots. Plavix does not have its anti-platelet effects until it is metabolized into its active form by the liver enzyme, CYP2C19.
"We determined that there are three critical problems that can lead to a level of non-response to Plavix," said Dr. Frederic J. Vagnini, M.D., FACS, a board certified cardiovascular surgeon who, after more than 20 years of performing heart surgery, has turned his clinical practice to the prevention of heart and related diseases. "First, in anyone an abnormality may be present within a gene abbreviated as CYP2C19 (and other variants) which significantly increases the risk of stroke or death due to clotting failure. Second, there are different variants or mutations between ethnic groups; some studies have indicated that one in three Caucasians and 40% of Asian of African-American populations have this abnormality.
"Among clinicians there have been discussions centering on differing dosing approaches. Perhaps the most important result of InoLife's DNA test is that each patient will be able to have an individually tailored course of treatment since some require longer periods on it," Vagnini stated.
InoLife Technologies feels that this is an important test for those who take Plavix or who may need to take Plavix in the future. The Company is very pleased that by addressing the black box warning, those who can be helped by this medication will be.
InoLife's Plavix Metabolizing Test is only available to physicians and medical professionals. It is not available for home use. Please ask your physician.
(Plavix is a trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.)
About InoLife Technologies, Inc
Positioned for growth and success in a burgeoning market, InoLife Technologies, www.inolifetech.com, is primarily focused on products, services and solutions that will enable state-of-the-art healthcare for today and the future for a diverse base of customers and end-users. The Company's mission is to identify, develop, integrate and bring to market innovative healthcare-based products and services that provide timely and practical solutions for both humans and companion animals. The primary products and services that InoLife is currently addressing focuses upon those specific products and services that provide key solutions through the innovative use of specific DNA testing and Genetic analysis systems.
The principal customers of InoLife's products and services are healthcare providers, physicians, practitioners, hospitals, outpatient facilities and veterinarians. Emphasis is being placed on individuals with a direct need for the DNA testing solutions. InoLife will be marketing and distributing its proprietary products to a wide variety of customers through e-commerce, direct sales, healthcare providers, distributors and retail sellers including pharmacies, specialty retailers and drugstores.
Forward-Looking Statements
Safe Harbor Statement under the Private securities Litigation Reform Act of 1995: The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements including, but not limited to, certain delays beyond the Company's control with respect to market acceptance of new technologies, products and services, delays in testing and evaluation of products and services, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.
